A phase 3, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of a single oral administration of nolasiban to improve pregnancy rates following IVF or ICSI in Day 3 and Day 5 fresh embryo transfer cycles

Trial Profile

A phase 3, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of a single oral administration of nolasiban to improve pregnancy rates following IVF or ICSI in Day 3 and Day 5 fresh embryo transfer cycles

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Nolasiban (Primary)
  • Indications Female infertility
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPLANT2
  • Sponsors ObsEva
  • Most Recent Events

    • 26 Feb 2018 According to an ObsEva media release, Follow-up data will include live birth rate, and 28-day neonatal safety, expected to be reported in the fourth quarter of 2018. Six-month infant follow-up is expected to be available in 2019.
    • 26 Feb 2018 According to an ObsEva media release, Herman Tournaye Head of the Centre for Reproductive Medicine at University Hospital Brussels is the principal investigator of this study.
    • 26 Feb 2018 Top line results presented in an ObsEva Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top